Making the Call in Type 2 Diabetes
GLP-1 Receptor Agonists and Reducing Stroke Risk
Glucagon-like peptide-1 receptor agonists.
Collins L, Costello RA. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Lancet. 2019;394(10193):121-130.
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS, Lee JK, Hung CS, Chen WJ. Diabetologia. 2021;64(12):2676-2686.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844.
Liraglutide and cardiovascular outcomes in type 2 diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016;375(4):311-322.
Stroke in COVID-19: a systematic review and meta-analysis.
Nannoni S, de Groot R, Bell S, et al. Int J Stroke. 2021;16(2):137-149.
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art.
Nauck MA, Quast DR, Wefers J, Meier JJ. Mol Metab. 2021;46:101102.
Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial.
Rosenstock J, Allison D, Birkenfeld AL, et al. JAMA. 2019;321(15):1466-1480.
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression.
van Sloten TT, Sedaghat S, Carnethon MR, et al. Lancet Diabetes Endocrinol. 2020;8(4):325-336.
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
Yun JS, Ko SH. Metabolism. 2021;123:154838.
Clinical Practice Guidelines
Standards of medical care in diabetes—2022.
American Diabetes Association. Diabetes Care. 2022;45(suppl 1):S1-S264.
Patient and Caregiver Resources
Association of Diabetes Care and Education Specialists
American Diabetes Association
Centers for Disease Control and Prevention: Diabetes Education and Support
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center
GLP-1 Receptor Agonists and Cardiovascular Risks
Module 1
| Faculty: | Kathleen Dungan, MD, MPH & Charles P. Vega, MD, FAAFP |
| Release: | 09/29/2022 |
| Expiration: | 09/29/2023 |
Educating Patients With T2D About Stroke Risk
Module 2
| Faculty: | Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES & Charles P. Vega, MD, FAAFP |
| Release: | 10/18/2022 |
| Expiration: | 10/18/2023 |
The Pathophysiology of T2D and Stroke
Module 4
| Faculty: | J. David Spence C.M., M.D., FRCPC, FAHA & Charles P. Vega, MD, FAAFP |
| Release: | 11/30/2022 |
| Expiration: | 11/30/2023 |
Managing Patients With T2D Who Are Recovering From A Stroke
Module 3
| Faculty: | J. David Spence C.M., MD, FRCPC, FAHA & Charles P. Vega, MD, FAAFP |
| Release: | 11/11/2022 |
| Expiration: | 11/11/2023 |
